{"id":22364,"date":"2025-09-03T15:13:43","date_gmt":"2025-09-03T19:13:43","guid":{"rendered":"https:\/\/www.ices.on.ca\/?post_type=journal_article&#038;p=22364"},"modified":"2025-09-17T15:41:25","modified_gmt":"2025-09-17T19:41:25","slug":"kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\/","title":{"rendered":"Kidney injury during treatment with aflibercept versus ranibizumab: a population-based study"},"content":{"rendered":"<p><strong>Purpose<\/strong> \u2014 Systemically administered anti-cancer VEGF inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on renal VEGF levels than ranibizumab. We compared the risk of kidney injury among patients receiving intravitreal aflibercept vs. ranibizumab.<\/p>\n<p><strong>Methods<\/strong> \u2014 This population-based new-user active-comparator cohort study in Ontario, Canada, evaluated 44,571 patients aged 66 years and older, newly treated with intravitreal aflibercept or ranibizumab between August 1, 2015, and July 31, 2019. The risk of adverse renal outcomes was compared while controlling for baseline and time-varying covariates.<\/p>\n<p><strong>Results<\/strong> \u2014 The composite renal outcome occurred in 12.0% (1,778\/14,863) of aflibercept recipients versus 10.0% (1,327\/13,289) of ranibizumab recipients (Relative risk: 1.00, 95% CI: 0.93\u20131.06 at 5 years follow up). No significant differences were observed across retinal disease subgroups<\/p>\n<p><strong>Conclusion<\/strong> \u2014 Intravitreal aflibercept and ranibizumab carry comparable risks of renal adverse events despite their distinct systemic pharmacodynamics.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Purpose \u2014 Systemically administered anti-cancer VEGF inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on renal VEGF levels than ranibizumab. We compared the risk of kidney injury among patients receiving intravitreal aflibercept vs. ranibizumab. Methods \u2014 This population-based new-user active-comparator cohort study in Ontario, Canada, evaluated 44,571 patients aged 66 [&hellip;]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[49,56],"migration-helper-qa-sample-set":[],"class_list":["post-22364","journal_article","type-journal_article","status-publish","hentry","topic-kidney-disease","topic-pharmacoepidemiology-and-drug-safety"],"acf":{"citation":"Campbell RJ, El-Defrawy SR, Gill SS, Shellenberger J, Whitehead M, Bell CM, Bronskill SE, Paterson JM, McIsaac MA. <em>Retina<\/em>. 2025; Sep 3 [Epub ahead of print].","source_url":"https:\/\/doi.org\/10.1097\/iae.0000000000004653","ices_scientist":[1203,17132,1159,1100],"site":[6736],"research_program":[6746],"news_release":"","journal_article":"","atlas":"","research_report":"","infographic":"","video":"","downloads":null,"links":null,"sitecore_item_id":"","sitecore_item_name":"","sitecore_field_values":"","previous_url":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICES | Kidney injury during treatment with aflibercept versus ranibizumab: a population-based study<\/title>\n<meta name=\"description\" content=\"Purpose \u2014 Systemically administered anti-cancer VEGF inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Kidney injury during treatment with aflibercept versus ranibizumab: a population-based study\" \/>\n<meta property=\"og:description\" content=\"Purpose \u2014 Systemically administered anti-cancer VEGF inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-17T19:41:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\\\/\",\"name\":\"ICES | Kidney injury during treatment with aflibercept versus ranibizumab: a population-based study\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2025-09-03T19:13:43+00:00\",\"dateModified\":\"2025-09-17T19:41:25+00:00\",\"description\":\"Purpose \u2014 Systemically administered anti-cancer VEGF inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Kidney injury during treatment with aflibercept versus ranibizumab: a population-based study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Kidney injury during treatment with aflibercept versus ranibizumab: a population-based study","description":"Purpose \u2014 Systemically administered anti-cancer VEGF inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Kidney injury during treatment with aflibercept versus ranibizumab: a population-based study","og_description":"Purpose \u2014 Systemically administered anti-cancer VEGF inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2025-09-17T19:41:25+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\/","name":"ICES | Kidney injury during treatment with aflibercept versus ranibizumab: a population-based study","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2025-09-03T19:13:43+00:00","dateModified":"2025-09-17T19:41:25+00:00","description":"Purpose \u2014 Systemically administered anti-cancer VEGF inhibiting therapies can cause severe kidney injury. Intravitreal aflibercept has a greater impact on","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/kidney-injury-during-treatment-with-aflibercept-versus-ranibizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Kidney injury during treatment with aflibercept versus ranibizumab: a population-based study"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/22364","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6746"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6736"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1100"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1159"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/17132"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1203"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=22364"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=22364"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=22364"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=22364"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=22364"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}